Radiofrequency ablation in pancreatic cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00108593" target="_blank" >RIV/00216224:14110/19:00108593 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/19:00072380

Výsledek na webu

<a href="http://dx.doi.org/10.33699/PIS.2019.98.11.441-449" target="_blank" >http://dx.doi.org/10.33699/PIS.2019.98.11.441-449</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.33699/PIS.2019.98.11.441-449" target="_blank" >10.33699/PIS.2019.98.11.441-449</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Radiofrequency ablation in pancreatic cancer

Popis výsledku v původním jazyce

Introduction: Clinical study evaluating the impact of intraoperative radiofrequency ablation in pancreatic cancer. Methods: Patients with histologically proved pancreatic cancer were included. Two groups were defined. In the RFA group (n=24) intraoperative RFA of the pancreatic tumour was performed. In the control group (n=24) only the bypass procedure was indicated (gastroenteric and hepaticojejunal anastomosis). No patient received neoadjuvant chemotherapy. Three-month morbidity and mortality, overall survival, quality of life, pain relief and radiological response were studied. Results: Overall three-month morbidity and mortality were 41.7% and 8.3%, respectively. RFA related morbidity and mortality reached 16.6% and 8.3%, respectively. The overall median survival time was 9.9 and 8.3 months in the RFA group and in the control group, respectively. The survival difference was not of statistical significance (p=0.758). QoL improvement after RFA was not proved. There was no statistically significant analgesic effect of RFA. Postoperative CT scan assessed as per RECIST criteria displayed progressive disease, stable disease, partial response and complete response in 41.6%, 45.8%, 8.3% and 0% cases, respectively. Conclusion: Intraoperative RFA of locally advanced and metastatic pancreatic cancer is a feasible palliative method. A survival benefit of this method remains doubtful, even though some positive results have been achieved in patients with localized, well-differentiated tumours. Although RFA was not associated with any impairment of the quality of life, no convincing evidence of a positive impact thereof on QoL was shown, either, during the three-month postoperative period. Pain relief was not achieved during the first 3 months after RFA.

Název v anglickém jazyce

Radiofrequency ablation in pancreatic cancer

Popis výsledku anglicky

Introduction: Clinical study evaluating the impact of intraoperative radiofrequency ablation in pancreatic cancer. Methods: Patients with histologically proved pancreatic cancer were included. Two groups were defined. In the RFA group (n=24) intraoperative RFA of the pancreatic tumour was performed. In the control group (n=24) only the bypass procedure was indicated (gastroenteric and hepaticojejunal anastomosis). No patient received neoadjuvant chemotherapy. Three-month morbidity and mortality, overall survival, quality of life, pain relief and radiological response were studied. Results: Overall three-month morbidity and mortality were 41.7% and 8.3%, respectively. RFA related morbidity and mortality reached 16.6% and 8.3%, respectively. The overall median survival time was 9.9 and 8.3 months in the RFA group and in the control group, respectively. The survival difference was not of statistical significance (p=0.758). QoL improvement after RFA was not proved. There was no statistically significant analgesic effect of RFA. Postoperative CT scan assessed as per RECIST criteria displayed progressive disease, stable disease, partial response and complete response in 41.6%, 45.8%, 8.3% and 0% cases, respectively. Conclusion: Intraoperative RFA of locally advanced and metastatic pancreatic cancer is a feasible palliative method. A survival benefit of this method remains doubtful, even though some positive results have been achieved in patients with localized, well-differentiated tumours. Although RFA was not associated with any impairment of the quality of life, no convincing evidence of a positive impact thereof on QoL was shown, either, during the three-month postoperative period. Pain relief was not achieved during the first 3 months after RFA.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

<a href="/cs/project/NV16-31314A" target="_blank" >NV16-31314A: Identifikace cirkulujících mikroRNA umožňujících prognostickou stratifikaci a selekci pacientů nejvíce profitujících z chirurgické léčby</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Rozhledy v chirurgii

ISSN

0035-9351

e-ISSN

1805-4579

Svazek periodika

98

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

9

Strana od-do

441-449

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85078072305